Medicine & Life Sciences
Acute Myeloid Leukemia
100%
venetoclax
73%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
61%
Survival
51%
Philadelphia Chromosome
50%
Protein-Tyrosine Kinases
50%
Leukemia, Myeloid, Chronic Phase
48%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
39%
Inotuzumab Ozogamicin
33%
Mutation
33%
Myelodysplastic Syndromes
32%
ponatinib
32%
asciminib
28%
Dasatinib
27%
Drug Therapy
26%
Therapeutics
24%
blinatumomab
22%
Leukemia, Myelomonocytic, Chronic
20%
Vincristine
18%
Decitabine
17%
Cytarabine
17%
Cyclophosphamide
16%
Stem Cell Transplantation
16%
Azacitidine
16%
Progression-Free Survival
15%
Dexamethasone
14%
Propensity Score
14%
Allogeneic Cells
14%
Cytogenetics
14%
Doxorubicin
13%
Primary Myelofibrosis
13%
Neoplasms
13%
bosutinib
13%
Recurrence
12%
Survival Rate
12%
Leukemia
11%
B-Cell Chronic Lymphocytic Leukemia
11%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
10%
PCI 32765
10%
Residual Neoplasm
10%
Cladribine
10%
Imatinib Mesylate
9%
Safety
9%
Blast Crisis
9%
Clofarabine
9%
Bone Marrow
8%
INCB018424
8%
Multivariate Analysis
7%
fludarabine
7%
Induction Chemotherapy
7%